T386:Lorenz:The Future of Toxicity Testing utilizing Robotics and Integration by Wako Automation
The Future of Toxicity Testing utilizing Robotics and Integration by Wako Laboratory Automation
David Lorenz1, Robert Bukar1, Paul Queeney1, Sam Michael2 and Menghang Xia, Ph.D.2
1 Wako Laboratory Automation Inc., 10420 Wateridge Circle, San Diego, CA 92121, USA
2 NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892-3370, USA
The National Toxicology Program (NTP), the NIH Chemical Genomics Center (NCGC), the US environmental Protection Agency (EPA) and the US Food and Drug Administration (FDA) have formed Tox21 partnership to shift chemical toxicity testing from traditional in vivo tests to high throughput in vitro methods. One goal of this collaboration is to test hundreds of thousands of chemicals against multiple in vitro assays to establish a signature of chemical compounds that can be used to predict in vivo human and rodent toxicity. To accomplish this task the NCGC required a robust automated platform and scheduling software that could bring together a diverse collection of equipment (plate readers, liquid handlers, incubators, centrifuge, etc.) to run a diverse array of biochemical and cell based assays producing reproducible high quality data. Wako Automation has delivered this 4th generation integrated platform based on the worlds most advanced scheduling software from Wako’s Kalypsys Systems product line, providing incredible speed, reliability, and high quality reproducible data. The NCGC utilizing Wako Automation’s testing platform will generate millions of data points that will be transformed into in vitro chemical signatures that may be used to study the mechanism of action of compounds, predict toxicity and minimize traditional animal toxicity testing.
|Click [+] for other articles on||The Market Place for Lab Automation & Screening||The Market Place|